Scarale Maria Giovanna, Fontana Andrea, Trischitta Vincenzo, Copetti Massimiliano, Menzaghi Claudia
Research Unit of Diabetes and Endocrine Diseases.
Unit of Biostatistics, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.
J Clin Endocrinol Metab. 2018 Nov 1. doi: 10.1210/jc.2018-01501.
Some studies have surprisingly indicated that serum adiponectin is positively related to mortality rate, thus casting doubts on its role as a therapeutic target for cardiovascular disease.
To summarize evidence about direction, strength and modulators of this controversial association.
MEDLINE, Web of Science, CINHAL, Cochrane Library and Scopus from inception through June 2018.
English-language prospective studies reporting the association between adiponectin and all-cause or cardiovascular mortality.
Two investigators independently extracted data and assessed study quality using standard criteria following the Preferred Reporting Items for Systematic Reviews and Meta-analyses and The Newcastle-Ottawa Scale, respectively. Pooled hazard ratios (HRs) (95% confidence intervals-CIs) were derived using a fixed or random effects models when appropriated and were expressed for one standard deviation (SD) increment of adiponectin.
We identified fifty-five (n=61,676 subjects) and twenty-eight (n=43,979 subjects) studies for all-cause and cardiovascular mortality, respectively. Pooled HRs, were 1.24 (1.17-1.31) and 1.28 (1.19-1.37) for all-cause and cardiovascular mortality, respectively. Similar results were obtained also for High Molecular Weight adiponectin. When meta-analyses were restricted to studies reporting data on natriuretic peptides a 43% and 28% reduction on a log scale of these associations were observed after natriuretic peptides adjustment.
Our results strongly points to a paradoxical association between high adiponectin levels and increased mortality rate, which is partly modulated by natriuretic peptides.
一些研究出人意料地表明,血清脂联素与死亡率呈正相关,因此对其作为心血管疾病治疗靶点的作用产生了怀疑。
总结关于这种有争议关联的方向、强度和调节因素的证据。
截至2018年6月的MEDLINE、科学网、CINHAL、考克兰图书馆和Scopus。
报告脂联素与全因或心血管死亡率之间关联的英文前瞻性研究。
两名研究者分别按照系统评价和Meta分析的首选报告项目以及纽卡斯尔-渥太华量表,独立提取数据并使用标准标准评估研究质量。合并风险比(HRs)(95%置信区间-CIs)在适当情况下使用固定或随机效应模型得出,并以脂联素增加一个标准差(SD)来表示。
我们分别确定了55项(n=61676名受试者)和28项(n=43979名受试者)关于全因死亡率和心血管死亡率的研究。全因死亡率和心血管死亡率的合并HRs分别为1.24(1.17-1.31)和1.28(1.19-1.37)。高分子量脂联素也得到了类似结果。当Meta分析仅限于报告利钠肽数据的研究时,在调整利钠肽后,这些关联在对数尺度上分别降低了43%和28%。
我们的结果有力地表明,高脂联素水平与死亡率增加之间存在矛盾的关联,这部分受利钠肽调节。